C30-NBOMe Stats & Data

Identity risk is high: “C30‑NBOMe” appears in unconfirmed/rumor lists and TripSit notes but lacks verified chemistry or human activity; this implies materials sold under this name are likely inactive, mislabelled, or unrelated to NBOMes—approach as an unknown. NBOMe compounds are often mis-sold as LSD on blotter and are active at microgram doses; if a “C30‑NBOMe” sample is actually an active NBOMe, mg‑range ‘test’ doses can be life‑threatening. Use reagent and, ideally, lab testing: Ehrlich turns purple for indoles (LSD); NBOMes/NBOHs will not give the LSD‑positive Ehrlich reaction and LSD fluoresces under UV whereas NBOMes generally do not—this helps rule in/out LSD when assessing blotter. NBOMe oral inactivity is not universal; some salts show oral bioavailability, and community reports conflict—so ‘swallowed and nothing happened’ is not a safe indicator that a blotter/powder is not an NBOMe. Avoid insufflation of unknown “C30‑NBOMe”: nasal dosing greatly increases onset speed and adverse events and has been linked to NBOMe overdoses and fatalities; never inject. If handling unknown powders, treat as potentially microgram‑potent: avoid eyeballing; if you insist on testing a tiny amount for analytical purposes, use a calibrated mg scale and volumetric techniques, label solutions, and keep far below known active NBOMe ranges. Be alert for warning signs of NBOMe toxicity (vasoconstriction with cold/numb extremities, severe agitation, hyperthermia, seizures); seek urgent medical care—severe NBOMe poisonings and deaths are documented. Avoid combining with stimulants or tramadol (seizure and cardiovascular risk) and with MAOIs/serotonergic poly‑drug use (serotonin toxicity risk). Because true pharmacology, identity, and stability remain unconfirmed for “C30‑NBOMe,” drug checking (FTIR/GC‑MS) is strongly advised and re‑dosing/escalation is strongly discouraged.